Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Leukos Biotech S.L.

Clinicaltrial registered3 Nov 2026

Leukos Biotech S.L.

3 Nov 2026: Trial registered · Evaluation of LB-208 (HTR1B Antagonist) in Adult Patients With Relapsed or Refractory Solid Tumours and Lymphoma. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
3 Nov 2026
Title
Evaluation of LB-208 (HTR1B Antagonist) in Adult Patients With Relapsed or Refractory Solid Tumours and Lymphoma
Conditions
Solid Tumor Malignancies, Lymphoma
Phase
Phase 1
Study Type
Interventional
Status
Recruiting
Countries
Spain
Country
Spain
Reference
NCT07914348
Location
Spain
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Leukos Biotech S.L.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from Spain

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.